At week 10 , a higher proportion of this population given vedolizumab was in remission ( 26.6 % ) than those given placebo ( 12.1 % ) ( nominal P = .001 ; relative risk , 2.2 ; 95 % confidence interval , 1.3-3 .6 ) .